Protective Effect of Resveratrol on the Brain in a Rat Model of Epilepsy.
Accumulating evidence has suggested resveratrol as a promising drug candidate for the treatment of epilepsy. To validate this, we tested the protective effect of resveratrol on a kainic acid (KA)-induced epilepsy model in rats and investigated the underlying mechanism. We found that acute resveratrol application partially inhibited evoked epileptiform discharges in the hippocampal CA1 region. During acute, silent and chronic phases of epilepsy, the expression of hippocampal kainate glutamate receptor (GluK2) and the GABAAreceptor alpha1 subunit (GABAAR-alpha1) was up-regulated and down-regulated, respectively. Resveratrol reversed these effects and induced an antiepileptic effect. Furthermore, in the chronic phase, resveratrol treatment inhibited the KA-induced increased glutamate/GABA ratio in the hippocampus. The antiepileptic effects of resveratrol may be partially attributed to the reduction of glutamate-induced excitotoxicity and the enhancement in GABAergic inhibition.
Department of Pharmacology, Anhui Medical University, Hefei, 230032, China.|Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Zhen
Z
Li
Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Zhuyan
Z
You
Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Min
M
Li
Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Liang
L
Pang
Department of Pharmacology, Anhui Medical University, Hefei, 230032, China.|Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.
Juan
J
Cheng
Department of Pharmacology, Anhui Medical University, Hefei, 230032, China. wangliecheng@ahmu.edu.cn.|Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China. wangliecheng@ahmu.edu.cn.
Liecheng
L
Wang
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D015536:Down-Regulation; D004833:Epilepsy, Temporal Lobe / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000187:drug effects*; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000187:drug effects; D018092:Kainic Acid Receptors / Q000187:drug effects; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D015854:Up-Regulation; D005680:gamma-Aminobutyric Acid / Q000187:drug effects*; D000097806:GluK2 Kainate Receptor
D000927:Anticonvulsants; D018690:Excitatory Amino Acid Agonists; D018698:Glutamic Acid; D007608:Kainic Acid; D018696:Neuroprotective Agents; D011963:Receptors, GABA-A; D018092:Kainic Acid Receptors; D000077185:Resveratrol; D013267:Stilbenes; D005680:gamma-Aminobutyric Acid; D000097806:GluK2 Kainate Receptor; C546242:Gabra1 protein, rat
Epilepsy; GABA; Glutamate; Hippocampus; Resveratrol